Mouse models of graft-versus-host disease: advances and limitations
- PMID: 21558065
- PMCID: PMC3097454
- DOI: 10.1242/dmm.006668
Mouse models of graft-versus-host disease: advances and limitations
Abstract
The limiting factor for successful hematopoietic stem cell transplantation (HSCT) is graft-versus-host disease (GvHD), a post-transplant disorder that results from immune-mediated attack of recipient tissue by donor T cells contained in the transplant. Mouse models of GvHD have provided important insights into the pathophysiology of this disease, which have helped to improve the success rate of HSCT in humans. The kinetics with which GvHD develops distinguishes acute from chronic GvHD, and it is clear from studies of mouse models of GvHD (and studies of human HSCT) that the pathophysiology of these two forms is also distinct. Mouse models also further the basic understanding of the immunological responses involved in GvHD pathology, such as antigen recognition and presentation, the involvement of the thymus and immune reconstitution after transplantation. In this Perspective, we provide an overview of currently available mouse models of acute and chronic GvHD, highlighting their benefits and limitations, and discuss research and clinical opportunities for the future.
Figures


Similar articles
-
Expanded donor natural killer cell and IL-2, IL-15 treatment efficacy in allogeneic hematopoietic stem cell transplantation.Eur J Haematol. 2008 Sep;81(3):226-35. doi: 10.1111/j.1600-0609.2008.01108.x. Epub 2008 Jun 28. Eur J Haematol. 2008. PMID: 18573173
-
Murine Models Provide New Insights Into Pathogenesis of Chronic Graft-Versus-Host Disease in Humans.Front Immunol. 2021 Sep 3;12:700857. doi: 10.3389/fimmu.2021.700857. eCollection 2021. Front Immunol. 2021. PMID: 34539630 Free PMC article. Review.
-
Preclinical models of acute and chronic graft-versus-host disease: how predictive are they for a successful clinical translation?Blood. 2016 Jun 23;127(25):3117-26. doi: 10.1182/blood-2016-02-699082. Epub 2016 Mar 18. Blood. 2016. PMID: 26994149 Free PMC article.
-
Insights into the pathogenesis of GvHD: what mice can teach us about man.Tissue Antigens. 2015 Jan;85(1):2-9. doi: 10.1111/tan.12497. Epub 2014 Dec 23. Tissue Antigens. 2015. PMID: 25532439 Review.
-
Quantity and Quality Reconstitution of NKG2A+ Natural Killer Cells Are Associated with Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation.Biol Blood Marrow Transplant. 2019 Jan;25(1):1-11. doi: 10.1016/j.bbmt.2018.08.008. Epub 2018 Aug 22. Biol Blood Marrow Transplant. 2019. PMID: 30142416
Cited by
-
Tirosin kinase inhibitors in chronic graft versus host disease: from bench to bedside.ScientificWorldJournal. 2011;11:1908-31. doi: 10.1100/2011/924954. Epub 2011 Oct 25. ScientificWorldJournal. 2011. PMID: 22125447 Free PMC article. Review.
-
Novel pre-clinical mouse models for chronic Graft-versus-Host Disease.Front Immunol. 2023 Jan 24;13:1079921. doi: 10.3389/fimmu.2022.1079921. eCollection 2022. Front Immunol. 2023. PMID: 36761159 Free PMC article.
-
Bat-mouse bone marrow chimera: a novel animal model for dissecting the uniqueness of the bat immune system.Sci Rep. 2018 Mar 16;8(1):4726. doi: 10.1038/s41598-018-22899-1. Sci Rep. 2018. PMID: 29549333 Free PMC article.
-
Antibody-drug conjugates plus Janus kinase inhibitors enable MHC-mismatched allogeneic hematopoietic stem cell transplantation.J Clin Invest. 2021 Dec 15;131(24):e145501. doi: 10.1172/JCI145501. J Clin Invest. 2021. PMID: 34730109 Free PMC article.
-
Macrophage regulation of graft-vs-host disease.World J Clin Cases. 2020 May 26;8(10):1793-1805. doi: 10.12998/wjcc.v8.i10.1793. World J Clin Cases. 2020. PMID: 32518770 Free PMC article. Review.
References
-
- Albert M. H., Liu Y., Anasetti C., Yu X. Z. (2005). Antigen-dependent suppression of alloresponses by Foxp3-induced regulatory T cells in transplantation. Eur. J. Immunol. 35, 2598–2607 - PubMed
-
- Alousi A. M., Weisdorf D. J., Logan B. R., Bolanos-Meade J., Carter S., Difronzo N., Pasquini M., Goldstein S. C., Ho V. T., Hayes-Lattin B., et al. (2009). Etanercept, mycophenolate, denileukin, or pentostatin plus corticosteroids for acute graft-versus-host disease: a randomized phase 2 trial from the Blood and Marrow Transplant Clinical Trials Network. Blood 114, 511–517 - PMC - PubMed
-
- Anderson B. E., McNiff J. M., Jain D., Blazar B. R., Shlomchik W. D., Shlomchik M. J. (2005). Distinct roles for donor- and host-derived antigen-presenting cells and costimulatory molecules in murine chronic graft-versus-host disease: requirements depend on target organ. Blood 105, 2227–2234 - PubMed
-
- Antin J. H., Weisdorf D., Neuberg D., Nicklow R., Clouthier S., Lee S. J., Alyea E., McGarigle C., Blazar B. R., Sonis S., et al. (2002). Interleukin-1 blockade does not prevent acute graft-versus-host disease: results of a randomized, double-blind, placebo-controlled trial of interleukin-1 receptor antagonist in allogeneic bone marrow transplantation. Blood 100, 3479–3482 - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources